Novartis files potential blockbuster eye drug with FDA

Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD. The Swiss pharma has cashed in a voucher allowing it to gain a faster six-month review for brolucizumab, hoping to… (pharmaphorum)

La notizia riportata su altri giornali

Avrebbero creato un cartello dicono i giudici (euronews)